Effects of aerobic exercise on vascular function in nondialysis chronic kidney disease: a randomized controlled trial

Endothelial dysfunction and arterial stiffness are nontraditional risk factors of chronic kidney disease (CKD)-related cardiovascular disease (CVD) that could be targeted with exercise. This study investigated the effect of moderate to vigorous aerobic exercise on vascular function in nondialysis CKD. In this randomized, controlled trial, 36 nondialysis patients with CKD (means +/- SE, age: 58 +/- 2 yr, estimated glomerular filtration rate: 44 +/- 2 ml.min(-1).1.73 m(-2)) were allocated to an exercise training (FAT) or control (CON) arm. The EXT group performed 3 x 45 min of supervised exercise per week at 60-85% heart rate reserve for 12 wk, whereas the CON group received routine care. Outcomes were assessed at 0 and 12 wk. The primary outcome, microvascular function, was assessed via cutaneous vasodilation during local heating measured by laser-Doppler flowmetry coupled with microdialysis. Participants were instrumented with two microdialysis fibers for the delivery of 1) Ringer solution and 2) the superoxide scavenger tempol. Conduit artery function was assessed via brachial artery flow-mediated dilation. Aortic pressure waveforms and pulse wave velocity were acquired with tonometry and oscillometry. Microvascular function improved after EXT (week 0 vs. week 12, EXT: 87 +/- 2% vs. 91 +/- 2% and CON: 86 +/- 2% vs. 84 +/- 3%, P = 0.03). At baseline, pharmacological delivery of tempol improved microvascular function (Ringer solution vs. tempol: 86 +/- 1% vs. 90 +/- 1%, P = 0.02) but was no longer effective after EXT (91 +/- 2% vs. 87 +/- 1%, P = 0.2), suggesting that an improved redox balance plays a role in FAT-related improvements. Brachial artery flow-mediated dilation was maintained after EXT (EXT: 2.6 +/- 0.4% vs. 3.8 +/- 0.8% and CON: 3.5 +/- 0.6% vs. 2.3 +/- 0.4%, P = 0.02). Central arterial hemodynamics and arterial stiffness were unchanged after EXT. Aerobic exercise improved microvascular function and maintained conduit artery function and should be considered as an adjunct therapy to reduce CVD risk in CKD.